Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders
Revista Alergia México · 31.03.2026 · 73 (1) · 17-25
DOI: 10.29262/ram.v73i1.1562 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Revista Alergia México, online erschienen am 31.03.2026. Verfasst von Ulises Noel García Ramírez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Clinical Immunology, Clínica de Asma de Difícil Control, Unidad Médica de Alta Especialidad, Centro Médico Nacional del Bajío, Instituto …. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma, Pulmonary Eosinophilia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico. METHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months. RESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed. CONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment. KEYWORDS: Benralizumab; Asthma; Asthma Control Test and Asthma Control Questionnaire (ACT); Eosinophils; Exhaled fraction of nitric oxide; Corticosteroids; Quality life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy and Clinical Immunology, Clínica de Asma de Difícil Control, Unidad Médica de Alta Especialidad, Centro Médico Nacional del Bajío, Instituto Mexicano del Seguro Social, León Guanajuato.
- Allergy and Clinical Immunology, Allergy service, Hospital General Regional 1 Lic. Ignacio García Téllez, Instituto Mexicano del Seguro Social, Mérida, Yucatán.
- Allergy and Clinical Immunology, Unidad de Especialidades Médicas, Secretaría de la Defensa Nacional, Naucalpan, Estado de México.
- Allergy and Clinical Immunology, Unidad de Especialidades Médicas, Secretaría de la Defensa Nacional. Naucalpan, Estado de México.
- Reumatology, Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, México.
- Médico Internista, Hospital General de Sub-Zona 7, San Francisco del Rincón, Guanajuato, México.
ORCID-Profile: Ulises Noel García Ramírez, Nadia Karina Aguilar Hinojosa, Saraid Cerda Reyes, Rosa Isela Campos Gutiérrez, Nidia Karen Castillón Benavides, Jorge Isaac Velasco Santos, Francisco Javier Núñez Martínez, Homero Garcés Flores, Gustavo Adolfo Arballo Rivera, Miriam Monzerrat Flores Razo, Paula Catalina Lizarazo Guiza
Zitieren
APA
García Ramírez, U. N., Aguilar Hinojosa, N. K., Cerda Reyes, S., Campos Gutiérrez, R. I., Castillón Benavides, N. K., Velasco Santos, J. I., Núñez Martínez, F. J., Garcés Flores, H., Arballo Rivera, G. A., Flores Razo, M. M., & Lizarazo Guiza, P. C. (2026). Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders. Revista Alergia México, 73(1), 17-25. https://doi.org/10.29262/ram.v73i1.1562
Vancouver
García Ramírez UN, Aguilar Hinojosa NK, Cerda Reyes S, Campos Gutiérrez RI, Castillón Benavides NK, Velasco Santos JI, et al. Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders. Revista Alergia México. 2026;73(1):17-25. doi:10.29262/ram.v73i1.1562
BibTeX
@article{GarcaRamrez2026,
author = {García Ramírez, Ulises Noel and Aguilar Hinojosa, Nadia Karina and Cerda Reyes, Saraid and Campos Gutiérrez, Rosa Isela and Castillón Benavides, Nidia Karen and Velasco Santos, Jorge Isaac and Núñez Martínez, Francisco Javier and Garcés Flores, Homero and Arballo Rivera, Gustavo Adolfo and Flores Razo, Miriam Monzerrat and Lizarazo Guiza, Paula Catalina},
title = {Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders},
journal = {Revista Alergia México},
year = {2026},
volume = {73},
number = {1},
pages = {17--25},
doi = {10.29262/ram.v73i1.1562}
}
EUVIMED